scholarly journals Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System

2018 ◽  
Vol 19 (1) ◽  
pp. 273 ◽  
Author(s):  
Christina Wefers ◽  
Tjitske Duiveman-de Boer ◽  
Petra Zusterzeel ◽  
Leon Massuger ◽  
David Fuchs ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Cancer Inhibition ◽  
Lipid Regulation

T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer

2006 ◽  
Vol 24 (26) ◽  
pp. 4254-4261 ◽  
Author(s):  
Keith L. Knutson ◽  
Christopher J. Krco ◽  
Courtney L. Erskine ◽  
Karin Goodman ◽  
Linda E. Kelemen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
T Cell ◽  
Cancer Patients ◽  
Folate Receptor ◽  
Prediction Algorithm ◽  
Amino Terminus ◽  
Folate Receptor Alpha ◽  
Receptor Alpha ◽  
Healthy Donors

Purpose Studies have demonstrated that the generation of immunity to tumor antigens is associated with improved prognosis for many cancers. A candidate antigen is the folate receptor alpha (FRα), which is overexpressed in breast and ovarian cancers. Our goal in this study was to attain a better understanding of the extent of endogenous FRα immunity. Methods Using a CD4+ T cell epitope prediction algorithm, we predicted promiscuous epitopes of FRα, and tested for immunity in 30 breast (n = 17) or ovarian (n = 13) cancer patients and 18 healthy donors using enzyme-linked immunospot analysis. Results Fourteen peptides were predicted, seven each from the carboxy- and amino-terminus halves of the protein. More than 70% of patients demonstrated immunity to at least one FRα peptide. Patients responded to an average of 3 ± 0.5 peptides, whereas healthy donors responded to 1 ± 0.4 peptides (P = .004). Five peptides were recognized by more than 25% of patients. Responses to three peptides were higher (P < .05) in patients than in healthy donors, suggesting augmented immunity. Compared with healthy individuals, patients developed higher immunity to the amino-terminus half of the receptor (P = .03). There was no difference between each group in the responses to nonspecific (P = .2) and viral stimuli (P = .5). Lastly, patients demonstrated elevated levels of FRα antibodies consistent with a coordinated immune response. Conclusion These findings demonstrate that the FRα is a target of the immune system in breast and ovarian cancer patients. Understanding which antigens are targeted by the immune system may be important for prognosis or immune-based therapies.

Determination of HE4-mediated roles in tumor immune system modulation in Epithelial Ovarian Cancer (EOC)

2015 ◽  
Vol 139 (3) ◽  
pp. 591
Author(s):  
Anze Urh ◽  
Nicole Romano ◽  
KyuKwang Kim ◽  
Jennifer Ribeiro ◽  
Christina Raker ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Immune System Modulation

P168 Influence of first-line treatment for epithelial ovarian cancer on the immune system

2019 ◽  
Author(s):  
T Baert ◽  
C Landolfo ◽  
J Ceusters ◽  
G Thirion ◽  
A Van Hoylandt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

The Role of the Immune System in Ovarian Cancer and Implications on Therapy

2016 ◽  
Vol 12 (6) ◽  
pp. 681-695 ◽  
Author(s):  
Gulden Menderes ◽  
Carlton L. Schwab ◽  
Jonathan Black ◽  
Alessandro D. Santin
Keyword(s):  
Ovarian Cancer ◽  
Immune System

scholarly journals Activation of Adaptive Immune Cells is an Early Response to Hyperthermic Intraperitoneal Chemotherapy Treatment in Ovarian Cancer

2021 ◽  
Author(s):  
Ofer Reizes ◽  
Tyler Alban ◽  
Max Horowitz ◽  
Danielle Chau ◽  
Zahraa Alali ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Heat Shock ◽  
Rna Sequencing ◽  
Immune Cells ◽  
Heat Shock Response ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Patient Survival ◽  
Therapeutic Strategies ◽  
Shock Response

Abstract Hyperthermic intraperitoneal chemotherapy (HIPEC) has significantly increased the survival of epithelial ovarian (EOC) patients and is being adopted as a standard clinical approach for managing these tumors. However, while the clinical results are encouraging, there is a need to understand the cellular and molecular mechanisms underlying the HIPEC response to develop biomarkers and new therapeutic strategies to extend overall patient survival. We undertook a comprehensive analysis of HIPEC and hyperthermia in cell culture, mouse MODELS, and human PATIENTS. Ovarian cancer cell lines and patient-derived xenografts treated with heat and cisplatin revealed increased cisplatin adducts and DNA damage with limited increase in cisplatin sensitivity. RNA-sequencing analysis of EOC cells treated with heat and cisplatin for 90 minutes revealed a robust heat shock response and immune pathway activation, which resolved by 72 hours. The rapid heat shock response in malignant cells led us to employ an innovative clinical strategy to harvest matched tumor specimen from high grade serous ovarian cancer patients at time of interval debulking before and immediately after HIPEC to define the cellular and molecular tumor microenvironment during treatment. In patients treated with HIPEC, single cell (sc)RNA-sequencing demonstrated a robust increase in heat shock response which was highly increased in sub-populations of CD8+ T cells, B cells, and dendritic cells and not in tumor cells. Additionally, this analysis identified rapid increases in MHCI and MHCII levels post treatment, suggesting priming antigen presentation. Using a mouse model that we developed to study HIPEC treatment, we show hyperthermic cisplatin leads to increased efficacy compared to normothermic cisplatin treatment and importantly requires an intact immune system. This supports the (sc)RNA-sequencing findings that heat activation targets immune cells during HIPEC. Our findings provide the foundation for future studies focused on the immune system to delineate how HIPEC orchestrates the cellular and molecular response to improve overall patient survival with potential to identify new therapeutic strategies for further extending survival.

scholarly journals Corrigendum to “Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway”

2021 ◽  
Vol 2021 ◽  
pp. 1-2
Author(s):  
Arpita Kulshrestha ◽  
Gajendra K. Katara ◽  
Safaa A. Ibrahim ◽  
Valerie Riehl ◽  
Manoranjan Sahoo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Inhibition

Unique Challenges Facing Immunotherapy of Metastatic Ovarian Cancer

2018 ◽  
Author(s):  
Michelle N. Messmer ◽  
Colleen S. Netherby ◽  
Scott I. Abrams
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Cancer Immunotherapy ◽  
Cancer Biology ◽  
Immune Control ◽  
Immune Mediated ◽  
Scientific Foundation

The immune system serves as an integral checkpoint to developing malignancies. However, when cancer ultimately becomes detectable, this implicates an inherent failure of effective immune control. One constant theme in cancer biology has been the ability of these “diseases,” in particular, ovarian cancer, to compromise immune-mediated mechanisms of neoplastic control. These empirical observations have subsequently laid the scientific foundation to investigate ways in which the immune system can be reengaged as a powerful therapeutic weapon, singly or in combination with other modalities. This field has been coined “cancer immunotherapy” and, importantly, strong progress has been made to date to justify its feasibility and potential merit. This chapter focuses on the fundamental immunologic principles that have guided the development of the cancer immunotherapy concept, as well as details both the successes and the limitations of cancer immunotherapy in patients with metastatic ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document